<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>741</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>14561737</PubmedId>
            <Abstract>We have mapped CD4+ T-cell epitopes located in three domains of the recombinant protective antigen of Bacillus anthracis. Mouse T-cell hybridomas specific for these epitopes were generated to study the mechanisms of proteolytic processing of recombinant protective antigen for antigen presentation by bone marrow-derived macrophages. Overall, epitopes differed considerably in their processing requirements. In particular, the kinetics of presentation, ranging from 15 (fast) to 120 min (slow), suggested sequential liberation of epitopes during proteolytic processing of the intact PA molecule. Pretreatment of macrophages with ammonium chloride or inhibitors of the major enzyme families showed that T-cell responses to an epitope presented with fast kinetics were unaffected by raising endosomal pH or inhibiting cysteine or aspartic proteinases, suggesting presentation independent of lysosomal processing. In contrast, responses to epitopes presented with slower kinetics were dependent on low pH and the activity of cysteine or aspartic proteinases indicating a requirement for lysosomal processing. In addition, responses to all epitopes, whether their presentation was dependent on low pH or not, were prevented by treatment of macrophages with broad spectrum serine proteinase inhibitors. Thus, our data are consistent with a model of sequential antigen processing within the endosomal system, beginning with a pre-processing step mediated by serine or metalloproteinases prior to further processing by lysosomal enzymes. Rapidly presented epitopes seemed to require only limited proteolysis at earlier stages of endocytosis, whereas the majority of epitopes required more extensive processing by neutral proteinases followed by lysosomal enzymes.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>52425-31</ArticlePages>
            <ArticleTitle>Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Musson</LastName>
                    <ForeName>Julie A</ForeName>
                </Author>
                <Author>
                    <LastName>Walker</LastName>
                    <ForeName>Nicola</ForeName>
                </Author>
                <Author>
                    <LastName>Flick-Smith</LastName>
                    <ForeName>Helen</ForeName>
                </Author>
                <Author>
                    <LastName>Williamson</LastName>
                    <ForeName>E Diane</ForeName>
                </Author>
                <Author>
                    <LastName>Robinson</LastName>
                    <ForeName>John H</ForeName>
                </Author>
            </Authors>
            <Affiliations>Musculoskeletal Research Group, Clinical Medical Sciences, Faculty of Medical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom.</Affiliations>
            <ArticleChemicalList>Antigens, Bacterial;Bacterial Toxins;CD4 Antigens;Culture Media;Epitopes;Epitopes, T-Lymphocyte;Peptides;Phenanthrolines;Recombinant Proteins;anthrax toxin;Ammonium Chloride;Metalloproteases;Aspartic Acid Endopeptidases;Cysteine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Ammonium Chloride(pharmacology); Animals; Antigen Presentation; Antigens, Bacterial; Aspartic Acid Endopeptidases(chemistry); Bacillus anthracis(metabolism); Bacterial Toxins(chemistry); Bone Marrow Cells(metabolism); CD4 Antigens(biosynthesis; chemistry); CD4-Positive T-Lymphocytes(metabolism); Culture Media(pharmacology); Cysteine(chemistry); Dose-Response Relationship, Drug; Endocytosis; Endosomes(metabolism); Epitopes; Epitopes, T-Lymphocyte(chemistry); Hydrogen-Ion Concentration; Kinetics; Lysosomes(metabolism); Macrophages(metabolism); Metalloproteases(chemistry); Mice; Mice, Inbred BALB C; Models, Molecular; Peptides(chemistry); Phenanthrolines(pharmacology); Protein Structure, Tertiary; Recombinant Proteins(metabolism); Time Factors</ArticleMeshHeadingsList>
            <Journal>
                <Volume>278</Volume>
                <Issue>52</Issue>
                <Title>The Journal of biological chemistry</Title>
                <Issn>1083-351X</Issn>
                <MedlineTa>J Biol Chem</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>PA 64-77</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IWSGFIKVKKSDEY</LinearSequence>
                        <StartingPosition>93</StartingPosition>
                        <EndingPosition>106</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13423.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1392</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table II</LocationOfData>
                <EpitopeId>29550</EpitopeId>
                <ReferenceStartingPosition>64</ReferenceStartingPosition>
                <ReferenceEndingPosition>77</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope occurs within protective antigen (PA20) mature chain. PA83 contains PA20 and PA63.  Swiss-Prot positions reflect precursor sequence numbering.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <TCellId>1313586</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB/c mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Dp7</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000000</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>183</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA 61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QSAIWSGFIKVKKSDEYTFA</LinearSequence>
                                        <StartingPosition>90</StartingPosition>
                                        <EndingPosition>109</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of a synthetic 20-mer PA peptide containing the CD4+ T-cell epitope by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of peptide, was measured. The epitope was presented optimally by 15 min. This was not blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl . Processing also was not blocked by inhibitors of cysteine, aspartic, or serine proteinases, or a metalloproteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A</LocationOfData>
                        <TCellId>14003</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB/c mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Dp7</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000000</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>183</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>recombinant protective antigen (rPA)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of naturally processed PA CD4+ T-cell epitopes by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of rPA, was measured. The epitope was presented optimally by 1-2 h. This was blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl. Processing was also blocked by inhibitors of cysteine, aspartic, or serine proteinases, and less efficiently blocked by a metalloproteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA 154-167</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PELKQKSSNSRKKR</LinearSequence>
                        <StartingPosition>183</StartingPosition>
                        <EndingPosition>196</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13423.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1392</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table II</LocationOfData>
                <EpitopeId>47349</EpitopeId>
                <ReferenceStartingPosition>154</ReferenceStartingPosition>
                <ReferenceEndingPosition>167</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope occurs within protective antigen (PA20) mature chain. PA83 contains PA20 and PA63.  Swiss-Prot positions reflect precursor sequence numbering.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A</LocationOfData>
                        <TCellId>14125</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB/c mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Dp16a</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000000</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>recombinant protective antigen (rPA)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of naturally processed PA CD4+ T-cell epitopes by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of rPA, was measured. The epitope was presented optimally by 1-2 h. This was blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl. Processing was also blocked by inhibitors of cysteine or serine proteinases, and less efficiently blocked by a metalloproteinase inhibitor. It was not blocked by an aspartic proteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <TCellId>1313598</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB/c mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Dp16a</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000000</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA 151-170</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LQLPELKQKSSNSRKKRSTS</LinearSequence>
                                        <StartingPosition>180</StartingPosition>
                                        <EndingPosition>199</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of a synthetic 20-mer PA peptide containing the CD4+ T-cell epitope by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of peptide, was measured. The epitope was presented within 15 min and was optimal by 1-2h. This was not blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl . Processing also was not blocked by inhibitors of cysteine, aspartic, or serine proteinases, or a metalloproteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA 547-560</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ITEFDFNFDQQTSQ</LinearSequence>
                        <StartingPosition>576</StartingPosition>
                        <EndingPosition>589</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13423.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1392</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table II</LocationOfData>
                <EpitopeId>28871</EpitopeId>
                <ReferenceStartingPosition>547</ReferenceStartingPosition>
                <ReferenceEndingPosition>560</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope occurs within protective antigen (PA63) mature chain. PA83 contains PA20 and PA63.  Swiss-Prot positions reflect precursor sequence numbering.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <TCellId>1313602</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000290</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB.K mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Kp55</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000290</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>110</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA 544-563</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GKDITEFDFNFDQQTSQNIK</LinearSequence>
                                        <StartingPosition>573</StartingPosition>
                                        <EndingPosition>592</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of a synthetic 20-mer PA peptide containing the CD4+ T-cell epitope by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of peptide, was measured. The epitope was presented within 15 min and was optimal by 1-2h. This was not blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl . Processing also was not blocked by inhibitors of cysteine, aspartic, or serine proteinases, or a metalloproteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A</LocationOfData>
                        <TCellId>14151</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000290</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB.K mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Kp55</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000290</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>110</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>recombinant protective antigen (rPA)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of naturally processed PA CD4+ T-cell epitopes by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of rPA, was measured. The epitope was the most rapidly processed and presented of the epitopes tested, with maximal processing occuring within 15 minutes. This was not blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl . Processing also was not blocked by inhibitors of cysteine, aspartic proteinases, or a metalloproteinase inhibitor. Processing was blocked by serine proteinase inhibitors.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA 659-672</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RYDMLNISSLRQDG</LinearSequence>
                        <StartingPosition>688</StartingPosition>
                        <EndingPosition>701</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13423.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1392</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table II</LocationOfData>
                <EpitopeId>56516</EpitopeId>
                <ReferenceStartingPosition>659</ReferenceStartingPosition>
                <ReferenceEndingPosition>672</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope occurs within protective antigen (PA63) mature chain. PA83 contains PA20 and PA63.  Swiss-Prot positions reflect precursor sequence numbering.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <TCellId>1313595</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB/c mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Dp66</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000000</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>183</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA 656-675</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>INDRYDMLNISSLRQDGKTF</LinearSequence>
                                        <StartingPosition>685</StartingPosition>
                                        <EndingPosition>704</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of a synthetic 20-mer PA peptide containing the CD4+ T-cell epitope by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of peptide, was measured. The epitope was presented optimally by 15 min. This was not blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl . Processing also was not blocked by inhibitors of cysteine, aspartic, or serine proteinases, or a metalloproteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A</LocationOfData>
                        <TCellId>14165</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB/c mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells.  Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Dp66</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000000</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>183</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>recombinant protective antigen (rPA)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of naturally processed PA CD4+ T-cell epitopes by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of rPA, was measured. The epitope was presented optimally by 1-2 h. This was not blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl . Processing was blocked by serine proteinase inhibitors. Processing was less efficiently blocked by a cysteine proteinase or metalloproteinase inhibitor. It was not blocked by an aspartic, proteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA 717-730</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>STNGIKKILIFSKK</LinearSequence>
                        <StartingPosition>746</StartingPosition>
                        <EndingPosition>759</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13423.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1392</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table II</LocationOfData>
                <EpitopeId>61780</EpitopeId>
                <ReferenceStartingPosition>717</ReferenceStartingPosition>
                <ReferenceEndingPosition>730</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope occurs within protective antigen (PA63) mature chain. PA83 contains PA20 and PA63.  Swiss-Prot positions reflect precursor sequence numbering.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <TCellId>1313604</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000290</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB.K mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells. Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Kp73</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000290</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>118</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA 714-733</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GDTSTNGIKKILIFSKKGYE</LinearSequence>
                                        <StartingPosition>743</StartingPosition>
                                        <EndingPosition>762</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of a synthetic 20-mer PA peptide containing the CD4+ T-cell epitope by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of peptide, was measured. The epitope was presented optimally by 15 min. This was not blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl. Processing also was not blocked by inhibitors of cysteine, aspartic, or serine proteinases, or a metalloproteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A</LocationOfData>
                        <TCellId>14167</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000290</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P13423.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1392</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>recombinant protective antigen (rPA)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>T-cell hybridomas were generated from CD4+ T-cell lines from recombinant PA-immunized BALB.K mice fused with BW5147 (TCR&lt;sup&gt;α-β-&lt;/sup&gt;) cells. Epitope specificity of T-cell lines from rPA immunized mice was deduced from their response to overlapping synthetic peptides representing the complete rPA sequence.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>Kp73</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Macrophage</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <SourceOrganismId>10000290</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>118</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>recombinant protective antigen (rPA)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13423.2</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1392</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>62</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The kinetics of presentation of naturally processed PA CD4+ T-cell epitopes by macrophages, formalin-fixed at 0, 15, 30, 60, 120, or 240 minutes after the addition of rPA, was measured. The epitope was presented optimally by 1-2 h. This was blocked by alkalinization of endosomes after treatment of macrophages with NH4Cl. Processing was also blocked by inhibitors of aspartic or serine proteinases. Processing was not blocked by a cysteine proteinase or a metalloproteinase inhibitor.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

